The steep EPS miss suggests deteriorating margins or higher costs. Monitor the conference call for guidance and cost-cutting plans. If no positive catalyst emerges, the stock may face selling pressure in the coming days.
Price Chart
Executive Summary
Akebia Therapeutics reported Q4 2025 EPS of $-0.05, a 900% miss vs consensus of $-0.01, with revenue of $51.7M in line with estimates. The significant earnings miss, despite in-line revenue, signals worsening profitability and likely weighs on the stock near-term.
Key Financial Metrics
Key Facts
- Q4 2025 EPS of $-0.05 missed consensus of $-0.01 by 900%
- Revenue of $51.7M was in line with consensus of $51.7M
- EPS miss is the largest in the last four quarters, reversing prior beats
- Conference call scheduled for May 7 at 8:00 a.m. EDT
Financial Impact
EPS miss of 900% vs consensus; revenue in line at $51.7M
Risk Factors
- Further earnings deterioration if cost trends persist
- Potential for guidance reduction on the call
- Low market cap ($364M) amplifies volatility on negative news
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3285448 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 30, 2026 13w ago | 8-K | $1.14 $0.9326 | ▼ −18.19% | ▼ −21.76% | $0.8650 (−24.12%) |
Apr 30, 2026 22w ago | Press Release | $1.40 $1.27 | ▲ +9.29% | ▲ +12.36% | $0.8650 (+38.21%) |
Feb 26, 2026 31w ago | 8-K | $1.32 $1.02 | ▼ −22.73% | ▼ −30.48% | $0.8650 (−34.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access